SAIPARENT Sai Parenterals Q1 FY27 results (Apr–Jun 2026) and concall
Sai Parenterals Limited reported a mixed Q1 FY27 with sequential revenue and PAT decline but improved gross and EBITDA margins. The quarter was marked by significant strategic capital allocation decisions, including the acquisition of majority stakes in Saicriti Pharma and Prathyak Laboratories to enhance manufacturing capacity and R&D capabilities. Noumed's long-term contract with EBOS Group was renewed, providing strong revenue visibility, while the Australian facility progresses towards completion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 435.1%, net profit up 457.7% against the same quarter last year.
| Line item | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 33 | 87 | 96 | 198 | 179 +435% |
| EBITDA | 5 | 16 | -4 | 26 | 24 +396% |
| Net profit | 1 | 8 | -7 | 13 | 8 +458% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
